Clinical Translational Research Seminar Series: Kathryn Grive, PhD скачать в хорошем качестве

Clinical Translational Research Seminar Series: Kathryn Grive, PhD

As part of the Advance RI-CTR Clinical and Translational Research Seminar Series, Dr. Kathryn Grive shared her early Advance RI-CTR Pilot Project research. Kathryn Grive, PhD, spoke about: “Effects of maternal cancer therapy on daughters’ ovarian health and fertility potential” To investigate the long-term effects of in utero taxane and immunotherapy exposure on exposed daughters’ ovarian reserve and reproductive potential, pregnant dams were treated with a single, human-relevant animal-equivalent dose of saline, docetaxel, anti-VEGF or anti-CTLA-4 monoclonal antibodies at embryonic day 16.5. Our studies demonstrate that in utero exposure to taxane-based therapy during late gestation has a significant effect on the long-term reproductive health of exposed daughters (as well as their daughters) and will be instrumental in helping clinicians better understand which chemotherapies for maternal malignancy are least detrimental to a developing fetus. Immunotherapy studies in this context are ongoing. About Dr. Grive Dr. Grive studies mechanisms of ovarian reserve establishment and maintenance: identifying novel regulators of the ovarian reserve, developing strategies for ovarian reserve protection during chemotherapy, and evaluating effect of ovarian reserve regulation of female lifespan and healthspan. This talk was scheduled for October 10th, 2025